RE:RE:RE:RE:RE:RE:I would like to see…lovingold, if xB3 has such value, and if it's going to be "monitized," then why are Dr. Deborah Rathjen, Midatech and Ladenburg Thalmann keeping that quiet and not helping to support the share prices of Bioasis and midatech with this great blue sky potential?
It's a magnificent promotional prediction and tool. Why are they avoiding it like the plague, allowing the share prices to crumble?
Look at the deal as filed, especially Midatech's filing. Why would they put together a plan and a deal so carefully, so complex, and they then purposefully avoid promoting its greatest value, the immense minitization potential of xB3?
I don't know, but the best guess I have is that they want it undervalued so that they can sell it off later for little money and without criticism for doing so. They can also say later that they didn't think xB3 was worth promoting, a position that would support them making a sweetheart deal a little down the road. If somebody else, a private company, buys it and then makes something valuable of it, then good for them. We didn't think it had that potential.
We all know things to be different than that, that xB3 is the unlying value of Bioasis, and not this silly Cresence stuff for which the Crescense people will end up with less than 1% of the value of Biodexa. That's how it's been valued. it in the filings. 0.6%, that's what it's worth, and Bioasis, at almost 10%, is worth almost 20 times that. Where does the rest of that value come from? xB3, that's where, and yet DrDR and her ganf are promoting the Cresence stuff.
Please, people, don't make their underestimation of you be real.
But Ladenburg Thallman and their partners almost certainly want xB3, and has set up this deal in a way that they will have it with no benefit to the current owners, the Bioasis shareholders.
jd